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Ulcerative colitis (UC) and Crohn’s Disease (CD) are the two most common forms of Inflammatory Bowel 
Diseases (IBD) marked by chronic and persistent inflammation. Neurotensin (NT), together with its receptor, 
NT receptor 1 (NTR1), are important mediators in intestinal inflammation and their expression is upregulated 
in the intestine of experimental colitis models and UC colonic biopsies. MicroRNAs (miRNAs) are short, 
non-coding RNA molecules which act as transcription repressors. We have previously shown that NT exposure 
upregulates miR-133α expression in human colonocytes NCM460 cells overexpressing NTR1 (NCM460-NTR1). 
Recently, miR-133α was further examined forits role in NT-associated proinflammatory signaling cascades and 
acute colitis in vivo. Our study shows that NT-induced miR-133α upregulation modulates NF-κB 
phosphorylation and promotes proinflammatory cytokine production. In addition, intracolonicinjection of 
antisense-miR-133α before colitis induction improves histological scores and proinflammatory cytokine 
transcription. More importantly, dysregulation of miR-133α levels and aftiphilin (AFTPH), a newly-identified 
miR-133α downstream target, is found only in UC patients, but not in patients with CD. Taken together, we 
identified NTR1/miR-133α/aftiphilin as a novel regulatory axis involved in NT-associated colonic inflammation 
in human colonocytes, acute colitis mouse model and in colonic biopsies from UC patients. Our results also 
provide evidence that colonic levels of NTR1, miR-133α and aftiphilin may also serve as potential biomarkers in 
UC. 
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Ulcerative colitis (UC) and Crohn’s disease (CD) are two 
most common forms of Inflammatory Bowel Diseases (IBD), 
which are characterized by chronic and persistent 
inflammation with relapsing and remitting episodes. 
Neurotensin (NT) is a proinflammatory neuropeptide found 
in the central nervous system and the intestine [1, 2], while NT 
receptor 1 (NTR1), which has a high affinity with NT, is 
expressed in neurons [3], colonic epithelial [2, 4-6], immune 
cells [7, 8] and colon cancer cell lines [9]. We and others have 
shown that during intestinal inflammation in experimental 
colitis mouse models [2, 5, 10, 11] and in the colon of UC 
patients [5], colonic NT and NTR1 expression is upregulated. 
Importantly, NT/NTR1 signaling promotes inflammation in 
colons in animal models induced with acute colitis [2,4], while 
mice deficient in NTR1 have attenuated colitis development 
and reduced mortality [4, 12] during the induction of 
experimental colitis. In addition, NT/NTR1 signaling has 
been shown to target on ERK and Akt activation in human 
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colonic epithelial cells [6, 9, 13]. The above evidence suggests 
that NT/NTR1 signaling is important in colonic 
inflammation both in colitis models and in human 
pathophysiology. 
MicroRNAs (miRNAs) are short, non-coding RNA 
molecules which act as transcription repressors. They 
represent targets of inflammatory agents and act as regulators 
of genes responsible for immune response [14-18]. Several 
studies demonstrated differential miRNA expression in the 
circulation [19-22] and in the colonic mucosa of UC [23-26] and 
CD [25, 27] patients as well as in the colon of experimental 
colitis mouse models [24]. However, whether miR-133α was 
involved in the development and progress of colitis was not 
known. Recently, we have shown that the binding of NT to 
NTR1 in human colonocytes NCM460 cells overexpressing 
NTR1 (NCM460-NTR1) modulates expression levels of 
several miRNAs[9], including miR-133α. Interestingly, 
during colon cancer development, miR-133α and its target 
genes regulate activation of ERK [28, 29] and Akt [30, 31] which 
are also targeted by NTR1 signaling [6, 9, 13].  
In our recent study, we investigated how miR-133α was 
involved in NT-associated colonic inflammation. We first 
examined miR-133α levels in two human colon epithelial cell 
lines, the non-transformed NCM460 cells (expressing low 
NTR1 levels) overexpressing NTR1 (NCM460-NTR1) and 
the colon cancer HCT116 cells expressing high NTR1 levels. 
Consistent with our previous findings [9], miR-133α 
expression was upregulated upon NT exposure in both cell 
lines. We then studied the association of miR-133α 
expression with colonic inflammation in vivo. NT was 
administered to wild type C57BL/6 mice through 
intracolonic administration as a mediator of acute colonic 
inflammation [2, 12]. RT-PCR analysis revealed that NT 
stimulation upregulated miR-133α expression in colon 
tissues in wild type mice. We also found that miR-133α 
expression was upregulated in two chemically induced 
mouse colitis models (2, 4, 6- trinitrobenzenesulfonic acid, 
TNBS; and dextran sodium sulfate, DSS). Together, these 
results imply that miR-133α may play a role in intestinal 
inflammation in vitro and in vivo. 
Dysregulation of mucosal homeostasis in IBD is caused 
by prolonged inflammation in the colonic mucosa. Therefore, 
we next examined the role of miR-133α in proinflammatory 
signaling responses in human colonocytes in vitro and in 
acute experimental colitis in vivo. The differential signaling 
activated by NTR1 activation in human colonocyte 
NCM460-NTR1 cells was studied after downregulation of 
miR-133α in vitro. Our results showed that miR-133α not 
only regulated ERK activation as previously described [28,29], 
but miR-133α silencing also reduced NF-κB activation and 
proinflammatory cytokine production. Several studies have 
shown that localized delivery of antisense oligonucleotides 
against NF-κB [32], TNF alpha [33] or miR-141 [34] are 
effective in ameliorating experimental colitis. To examine 
the impact of miR-133α in vivo we reduced local colonic 
miR-133α levels by intracolonic injection of antisense- 
miR-133α oligonucleotides prior to acute colitis induction by 
TNBS administration. Mice administered with antisense- 
miR-133α oligonucleotides showed improved histological 
score and reduced proinflammatory cytokine production. In 
addition, miR-133α level was mainly upregulated in colonic 
epithelial cells in mice with colitis and majority of antisense 
oligonucleotides delivered intracolonically was confined to 
colonic epithelial cells in vivo [34].  Taken together, our data 
showed that reducing miR-133α expression in colonic 
epithelial cells through local delivery of antisense- miR-133α 
oligonucleotides in vivo attenuates development of acute 
colitis. 
As described above miRs inhibit transcription of different 
genes serving as downstream targets thereby affecting a wide 
range of diseases, including inflammation [35]. MiRs exert 
their effect by binding 3’untranslated regions (UTRs) of 
transcript [36], thereby repressing deadenylation during 
translation and promoting mRNA degradation [37]. Several 
downstream targets have been identified for miR-133α that 
play a role in inflammation (UCP2 [38]), cancer (EGFR [39,40], 
GSTP1 [41], PNP [42], TAGLN2 [42, 43]) and oxidative stress 
(GM-CSF [44]). Using in silico search in 3 online databases 
[miRBase (www.mirbase.org) and PicTar 
(http://pictar.mdc-berlin.de);TargetScanHuman 
(www.targetscan.org)], we have identified a novel miR-133α 
target, aftiphilin (AFTPH). NT stimulation of human 
colonocytes or miR-133α overexpression in these cells 
lowered AFTPH mRNA levels.  The role of AFTPH in 
cellular function has been studied in a small number of 
studies. AFTPH contains binding motifs for the structural 
protein clathrin [45] and is localized in trans-golgi network 
(TGN) [46]. Although TGN morphology is not affected by 
AFTPH gene silencing [47], downregulated AFTPH levels 
promote dysregulated exocytosis of Weibel-Palade bodies in 
endothelial cells [48].  
The clinical relevance of our findings was also examined 
by measuring the levels of miR-133α and its novel 
downstream target, AFTPH, in colonic cDNA samples from 
UC and CD patients and their normal controls. We showed 
that increased miR-133α, but reduced AFTPH transcription 
were detected in mucosal biopsies of UC, but not CD 
patients, when compared to normal controls. In addition, we 
have also investigated the role of AFTPH, a protein 
responsible for intracellular trafficking [45] and exocytosis [48], 
in proinflammatory signaling cascades. Consistent with the 
results from our miR-133α studies, AFTPH gene-silencing in 
vitro enhanced NF-κB phosphorylation and IL-1β production 
in human colonocytes. Therefore, dysregulation in miR-133α 
and AFTPH expression modulates proinflammatory 
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responses in human colonocytes and possibly in the mucosa 
in colons during colitis and IBD. 
One of the important strategies of drug development in 
IBD is to limit chronic inflammation. Understanding the 
mechanism(s) of IBD-related inflammation enables us to 
target new genes and /or signaling pathways. Our recent 
study identified a novel NTR1/miR-133α/AFTPH network 
involved in proinflammatory signaling regulation in colonic 
epithelial cells in vitro and in vivo, present evidence implying 
their potential use as biomarkers for UC. Consequently, 
future work will explore the effect of reducing AFTPH 
expression in acute colitis development by intracolonic 
administration of siRNA against AFTPH. In addition, 
although MyoD and myogenin are the two known 
transcription factors promoting miR-133α transcription 
during muscle development [49, 50], the molecular mechanisms 
for regulating miR-133α during inflammation has not been 
examined. Studies on the mechanism(s) related to the 
regulation of expression of miR-133α will provide more 
insights to the proinflammatory response during colitis.  
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